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Abstract
Gastrin-releasing peptide receptor (GRPR) and the epi-
dermal growth factor receptor (EGFR) are expressed in
several cancers including non–small cell lung carci-
noma (NSCLC). Here we demonstrate the activation of
EGFR by the GRPR ligand, gastrin-releasing peptide
(GRP), in NSCLC cells. GRP induced rapid activation of
p44/42 MAPK in lung cancer cells through EGFR. GRP-
mediated activation of MAPK in NSCLC cells was abro-
gated by pretreatment with the anti-EGFR–neutralizing
antibody, C225. Pretreatment of NSCLC cells with
neutralizing antibodies to the EGFR ligands, TGF-A or
HB-EGF, also decreased GRP-mediated MAPK activa-
tion. On matrix metalloproteinase (MMP) inhibition,
GRP failed to activate MAPK in NSCLC cells. EGF and
GRP both stimulated NSCLC proliferation, and inhi-
bition of either EGFR or GRPR resulted in cell death.
Combining a GRPR antagonist with the EGFR tyrosine
kinase inhibitor, gefitinib, resulted in additive cytotoxic
effects. Additive effects were seen at gefitinib concen-
trations from 1 to 18 MM, encompassing the ID50 values of
both gefitinib-sensitive and gefitinib-resistant NSCLC
cell lines. Because a major effect of GRPR appears to
be promoting the release of EGFR ligand, this study
suggests that a greater inhibition of cell proliferation
may occur by abrogating EGFR ligand release in con-
sort with inhibition of EGFR.
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Introduction
Although lung cancer is the most commonly occurring
cancer worldwide, available treatment options are often inef-
fective. The 5-year survival rates of patients suffering from
lung cancer remain low at less than 15% [1]. Non–small cell
lung carcinoma (NSCLC) accounts for 80%of all lung cancer
cases. NSCLC tumors are known to express high levels of
the epidermal growth factor receptor (EGFR) [2], and agents
targeting EGFR have shown promise for NSCLC treatment.
Overexpression of EGFR increases cellular proliferation
and is associated with poor prognosis in a number of tumor
types, including NSCLC [3]. Several signaling pathways lie
downstream of EGFR including PI3-kinase, MAPK, signal
transducers and activators of transcription (STAT) proteins,
and PLCg-1. A number of clinical trials in NSCLC have been
carried out using novel drugs targeting EGFR. Although a
correlation between levels of EGFR expression and treatment
response was not observed, some late-stage patients with
adenocarcinoma of the lung have responded favorably to
EGFR inhibition with EGFR tyrosine kinase inhibitor, ZD1839
(gefitinib) [4]. Response rates of lung cancer patients to EGFR
inhibition in clinical trials were less than 15%, despite an almost
universal expression of the EGFR protein. This has prompted
questions about the mechanisms of response to EGFR inhib-
itors. Recently, EGFR mutations have been described in
patients who are associated with increased susceptibility to
ZD1839; however, some patients with partial response did not
have a mutated EGFR [5,6]. The sensitivity of NSCLC cell lines
to gefitinib varies over a 100-fold range; cell lines with EGFR
mutations generally display ID50 values in the 0.1 to 1.0 mM
range, whereas cell lines lacking mutations generally display
ID50 values in the 10 to 20 mM range [5,6].
G-protein – coupled receptors (GPCRs) are seven-
transmembrane spanning proteins that are involved in a
number of cellular processes. We previously demonstrated
expression of the GPCR gastrin-releasing peptide receptor
Address all correspondence to: Jill M. Siegfried, PhD, Department of Pharmacology,
University of Pittsburgh, E1340, 200 Lothrop Street, Pittsburgh, PA 15213.
E-mail: siegfrie@server.pharm.pitt.edu
1This work was supported by a grant (U01 CA84968) from the Early Detection Research
Network (J.R.G. and J.M.S.), a grant (P50 CA90440) from the Specialized Program of
Research Excellence (J.M.S.), and a National Institutes of Health grant (1 R01 CA 098372-01).
S.M.T. and V.Y.W.L. were supported by Career Development Awards from the University of
Pittsburgh Lung Cancer SPORE.
Received 30 June 2004; Revised 1 November 2004; Accepted 3 November 2004.
Copyright D 2005 Neoplasia Press, Inc. All rights reserved 1522-8002/05/$25.00
DOI 10.1593/neo.04454
Neoplasia . Vol. 7, No. 4, April 2005 pp. 426 – 431 426
www.neoplasia.com
RESEARCH ARTICLE
(GRPR) in NSCLC [7]. Neutralizing antibody (2A11) to the
GRPR ligand, gastrin-releasing peptide (GRP), resulted in
the cell death of head and neck squamous cell carcinoma
(HNSCC) [8]. Several GPCRs including GRPR have been
reported to trigger signaling pathways through EGFR [9] in
a number of cell systems [10].
Both EGFR and GRPR are activated in NSCLC by their
corresponding ligands, TGF-a and GRP, in an autocrine
manner. In this study, we examined the interactions between
GRPR and EGFR in NSCLC cell lines because both recep-
tors are expressed in NSCLC and are potential targets for
therapy. Stimulation by GRP results in rapid activation of
EGFR and signaling through MAPK downstream of EGFR,
which is dependent on EGFR activation. We also demon-
strated that matrix metalloproteases (MMPs) play a role in
GRP-mediated activation of EGFR, and that combining
inhibitors of these pathways increases the antiproliferative
activity observed against lung cancer cells.
Materials and Methods
Cells and Reagents
Lung adenocarcinoma cell line 201T was maintained in
BME supplemented with 10% heat-inactivated fetal bovine
serum (Invitrogen, Carlsbad, CA) [7]. Growth factors, EGF
and GRP, were obtained from Sigma-Aldrich Corporation
(St. Louis, MO). The EGFR-specific small molecule tyrosine
kinase inhibitors, PD153035 (Calbiochem-Novabiochem
Corporation, San Diego, CA) and ZD1839 (gefitinib, or Iressa),
obtained from AstraZeneca Pharmaceuticals, LP (Wilmington,
DE), were used to inhibit EGFR. In addition, an anti-EGFR
antibody C225 (ImClone Systems Incorporated, New York,
NY) specific to the extracellular domain of EGFR was
used to block EGFR ligand binding. The GRP antagonist,
PD176252, was obtained from Pfizer, Inc. (New York, NY)
[11]. Broad-spectrum inhibitors, Marimastat (British Biotech,
Oxford, UK) and GM6001 (Calbiochem-Novabiochem Cor-
poration), were used to inhibit cellular MMPs. Antibodies to
p42/44 phospho-MAPK and MAPK were obtained from Cell
Signaling Technologies (Beverly, MA). Anti-EGFR antibody
was obtained from Upstate Biotechnology (Lake Placid, NY).
Anti–phospho-tyrosine antibody PY99 was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti–b-actin
antibody was obtained from Oncogene Research Products
(Boston, MA).
In Vitro Assay
Approximately 2  105 cells/ml were plated in 100-mm
dishes in BME supplemented with 10% heat-inactivated
fetal bovine serum. Cells were allowed to adhere overnight
and serum-starved for 48 hours with daily changes in BME
media. Cells were pretreated with inhibitors or antibodies
for 2 hours followed by stimulation with either the vehicle
(water) or growth factors, EGF (10 ng/ml) or GRP (400 nM),
for 10 minutes in the absence or presence of inhibitors.
Cells were harvested in cold lysis buffer (10 mM Tris–HCl,
pH 7.6, 50 mM Na4P2O7, 50 mM NaF, 1 mM NaV3O4, 1%
Triton X-100, and 1 protease inhibitor cocktail tablet that
included a broad-spectrum potent inhibitor of protein tyro-
sine phosphatases; Roche, Mannheim, Germany) after two
washes in ice-cold PBS.
Immunoprecipitation and Immunoblotting
Cell lysates were briefly sonicated on ice and cleared
by centrifugation at 4jC for 5 minutes at 14,000 rpm. Protein
quantification was carried out using the Protein Assay Solu-
tion (BioRad Laboratories, Hercules, CA). For immunoprecipi-
tations, 100 mg of protein was mixed with 3 mg of anti-EGFR
antibody (Upstate Biotechnology) and 40 ml of Protein
G-agarose beads (Invitrogen). Lysates were placed on an
orbital shaker overnight at 4jC. The beads were preci-
pitated by centrifugation, washed thrice in ice-cold lysis
buffer, and resuspended in 4 sample buffer. Beads were
boiled for 5 minutes. The proteins were resolved on an
8% SDS-PAGE gel and transferred to a nitrocellulose mem-
brane in a semidry transfer apparatus. Membranes were
blocked in 5% milk followed by immunoblotting with the
appropriate antibodies.
In Vitro Proliferation and Cytotoxicity Assays
NSCLC cells 201T were plated at a density of 2  104
cells/ml in 24-well plates in BME supplemented with 10%
heat-inactivated fetal calf serum and treated after 24 hours.
For proliferation assays, cells were serum-starved for
24 hours followed by stimulation with either EGF (10 ng/ml)
or GRP (400 nM) either in the presence or absence of C225
(6 mg/ml). For cytotoxicity assays, cells were treated with
either vehicle control (DMSO), ZD1839 (Iressa), or PD176252
in serum-containing media for 72 hours. Cell viability was
assessed by measuring the number of metabolically active
cells using the MTT assay. IC50 dose was calculated using
PRISM Version 3 (Graphpad Software, San Diego, CA).
Results
Lung Cancer Cells Express EGFR
A panel of six human NSCLC cell lines and the immortal-
ized human bronchial epithelial cell line IB3-1 were examined
for EGFR expression by immunoblotting. All cell lines ex-
pressed the EGFR receptor (Figure 1). An adenocarcinoma
line (201T) was demonstrated to express moderate levels
of the EGFR receptor. In addition, this line was found to
express GRPR by immunoblotting (data not shown). On the
basis of the simultaneous expression of both receptors, we
chose this line for further studies.
GRP Stimulation Increases EGFR and MAPK
Phosphorylation
Adenocarcinoma cells 201T were serum-starved for
72 hours prior to growth factor stimulation. Treatment with
GRP resulted in phosphorylation of EGFR at 10 minutes
(Figure 2A). EGF at a concentration that gives maximal
EGFR stimulation was used as a positive control, and is
higher than what can be achieved by autocrine release of
GRPR Signaling Through EGFR in Lung Cancer Cells Thomas et al. 427
Neoplasia . Vol. 7, No. 4, 2005
ligand. GRP stimulation for 10 minutes also resulted in
activation of MAPK in 201T cells in a time-dependant
manner (Figure 2B). Maximal phosphorylation of MAPK
was achieved at 10 minutes. A squamous cell carcinoma
line (273T) also demonstrated EGFR and MAPK activation
on GRP stimulation (data not shown).
To investigate the mechanism whereby GRP activates
MAPK in NSCLC cells, we pretreated 201T cells with EGFR-
specific tyrosine kinase inhibitors, PD153035 (100 nM)
(Figure 2C) or C225 (6 mg/ml) (Figure 2D). Again, EGF, alone
and with EGFR inhibitors at a concentration that gives
maximal stimulation of EGFR, was used as a positive and
negative control, respectively. After 2 hours of preincuba-
tion, the cells were stimulated with GRP in the presence
or absence of inhibitors for 10 minutes. Activated and total
levels of MAPK were determined by immunoblotting. Both
EGF and GRP failed to activate MAPK when EGFR was
inhibited in NSCLC cells, whereas both were able to acti-
vate MAPK in the absence of EGFR inhibition. This indi-
cates that GRP activates MAPK primarily through EGFR
in NSCLC cells.
TGF- and HB-EGF Are Involved in GRP-Mediated
EGFR Activation
We have previously demonstrated that GRP-mediated
EGFR activation in head and neck cells occurs through
extracellular ligand binding to the receptor. EGFR ligands,
TGF-a and heparin binding-EGF (HB-EGF), are present on
the membrane surface as proligands. Cleavage of these
proligands releases activated ligands into the extracellular
milieu. We also previously investigated the role of both these
ligands in GRP-mediated EGFR activation in HNSCC. Neu-
tralizing antibodies to TGF-a and HB-EGF were preincu-
bated with 201T cells for 2 hours prior to GRP stimulation.
Cell lysates were analyzed by immunoblotting for activated
and total MAPK. Both TGF-a– and HB-EGF–neutralizing
antibodies abrogated GRP-mediated MAPK activation in
NSCLC cells (Figure 3, A and B, respectively). TGF-a–
neutralizing antibody had no effect on EGF stimulation of
MAPK, as expected. These results imply that on GRP
stimulation, both EGFR proligands, TGF-a and HB-EGF,
are cleaved from the membrane surface and released into
the extracellular milieu. Once released from the mem-
brane surface, the ligands bind to the extracellular domain
of EGFR in an autocrine fashion, activating the receptor.
MMPs Are Required for GRP-Mediated EGFR Activation
MMPs are involved in the processing of EGFR proligands
bound to the membrane surface. Blocking MMP activity with
broad-spectrum MMP inhibitors abrogated autocrine activa-
tion of EGFR in head and neck cancer cells [9,12]. To
investigate the role of MMPs in GRP-mediated EGFR acti-
vation, 201T cells were pretreated with either of two MMP
inhibitors, Marimastat (20 nM) or GM6001 (200 nM). After
2 hours of pretreatment with the MMP inhibitors, cells were
stimulated with GRP in the presence or absence of the MMP
inhibitors. Cell lysates were then harvested and analyzed by
immunoblotting for activated and total MAPK. Inhibition of
Figure 2. GRP stimulation activates EGFR and downstream MAPK. NSCLC
cells 201T were serum-starved for 72 hours followed by stimulation with
either EGF (10 ng/ml) or GRP (400 nM) for various time points. (A) Cell
lysates were immunoprecipitated with EGFR and subjected to immunoblot-
ting with phospho-tyrosine antibody PY99. The membrane was stripped and
immunoblotted for total EGFR to demonstrate an equal loading of protein in
all lanes. (B) Cell lysates were analyzed for activated and total p42/44 MAPK
levels by immunoblotting. NSCLC cells were serum-starved for 72 hours
followed by pretreatment with EGFR-specific inhibitors, (C) PD153035 or
(D) C225, for 2 hours. Untreated cells or inhibitor-treated cells were then
stimulated with EGF (10 ng/ml) or GRP (400 nM) for 10 minutes. Cell lysates
were analyzed for phospho-p42/44 MAPK and total p42/44 MAPK levels
by immunoblotting.
Figure 1. NSCLC cells express EGFR. Western blot analysis demonstrating
levels of EGFR in NSCLC cells including adenocarcinoma (201T). Immor-
talized epithelial cells (IB31) also expressed EGFR. The same membrane
was probed for -actin to demonstrate an equal loading of protein in all lanes.
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MMPs abrogated GRP-mediated, but not EGF-mediated,
MAPK activation in NSCLC cells (Figure 4). This suggests
that on GRP stimulation of NSCLC cells, MMPs are activated
and cleave the EGFR proligands from the membrane surface
to facilitate EGFR activation.
GRP Stimulates Proliferation of NSCLC Cells
through EGFR
Serum-starved NSCLC cells 201T were stimulated with
either EGF or GRP for 48 hours in the presence or absence
of C225 (6 mg/ml) followed by MTT assay. Both EGF and
GRP stimulated 201T cell proliferation (Figure 5). GRP
stimulated 201T cell proliferation significantly compared
to the vehicle control (P = .004) as determined by the
Wilcoxon-Mann-Whitney test using STATXACT (Version 6;
Cytel Software Cooperation, Cambridge, MA). Both EGF an
GRP-mediated 201T proliferation were abrogated by EGFR
inhibition with antibody C225. This demonstrates that EGFR
mediates 201T cell proliferation that is initiated by GRP.
EGFR and GRPR Can Be Effectively Targeted in
NSCLC Cells
The antitumor efficacy of targeting EGFR and GRPR with
specific small molecule inhibitors was tested in vitro. NSCLC
cells 201T were treated with varying concentrations of either
EGFR-specific tyrosine kinase inhibitor ZD1839 or GRPR
antagonist PD176252 for 72 hours followed by MTT assay.
The IC50 for the inhibitors was determined. ZD1839 was
cytotoxic to 50% of the cells at a concentration of 18 mM,
whereas PD176252 had an IC50 of 8 mM (Figure 6A). We then
combined both inhibitors at sub-IC50 concentrations to in-
vestigate the antitumor effects of dual receptor blockade in
vitro. NSCLC cells were treated with a combination of
ZD1839 and PD176252 for 72 hours followed by the MTT
assay. Both compounds inhibited NSCLC cell growth addi-
tively at concentrations lower that the IC50 for either com-
pound alone (15 mMZD1839 and 5 mMPD176252), achieving
more than 60% cell kill with the combination (Figure 6B).
Combining lower, more clinically relevant concentrations
(1 and 2 mM) of ZD1839/gefitinib with PD176252 also results
in additive cytotoxic effects (30–40% cell kill for the combi-
nation compared to 10% to 18% with either drug alone;
Figure 6C). Combining the two compounds at the IC50 con-
centrations resulted in 99% cell kill (data not shown). This
indicates that combined targeting of EGFR and GRPR using
small molecule inhibitors is more cytotoxic compared to in-
hibition of either receptor alone in NSCLC cells, throughout
the concentration–response range.
Discussion
Increased expression levels of EGFR have been reported in
over 70% of NSCLC [13]. EGFR overexpression in NSCLC
cells increases cellular proliferation and correlates with poor
outcome [14,15]. In addition, NSCLC cells grown in serum-free
medium express an autocrine loop for GRPR and GRP [16].
We have also demonstrated that GRP is mitogenic in many
Figure 3. GRP stimulation results in EGFR activation through extracellular
ligand binding to the receptor. Serum-starved NSCLC cells were pretreated
for 2 hours with (A) TGF-a–neutralizing antibody (6 g/ml) or (B) HB-EGF–
neutralizing antibody (6 g/ml) followed by EGF (10 ng/ml) or GRP (400 nM)
stimulation for 10 minutes. Immunoblotting was carried out for phospho-p42/44
MAPK and total p42/44 MAPK.
Figure 4. MMPs are involved in GRP-mediated EGFR activation. Serum-
starved NSCLC cells were pretreated with MMP inhibitors, Marimastat or
GM6001, for 2 hours prior to GRP (400 nM) stimulation. Immunoblotting was
carried out with phospho-p42/44 MAPK and total p42/44 MAPK.
Figure 5.GRP stimulates NSCLC cell proliferation through EGFR. NSCLC cells
were serum-starved for 24 hours followed by stimulation with EGF (10 ng/ml)
or GRP (400 nM) either in the presence or absence of anti-EGFR antibody C225
(6 g/ml) for 48 hours. Metabolically active cells were estimated by MTT assay.
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NSCLC cell lines and that autocrine loops for GRPR and its
ligands are present [7]. Here we demonstrate for the first
time the activation of EGFR and one of its downstream path-
ways by GRP in NSCLC cells.
Several signaling pathways are triggered following the
activation of EGFR including MAPK and PI3K, contributing to
cell proliferation and survival. We and others have demon-
strated that GPCRs mediate the activation of EGFR in
HNSCC [9]. In the present study, we demonstrate that
GRP stimulation of NSCLC cells results in activation of
EGFR and the MAPK pathway downstream of EGFR. More-
over, abrogation of EGFR by EGFR-specific tyrosine kinase
inhibitors also blocks GRP-mediated MAPK activation. This
result corroborates our previous findings in HNSCC where
GRP activated MAPK primarily through EGFR, and suggests
that this pathway cross-talk is a general effect found in many
tumor types [9]. GRP has been reported to have a low affinity
for the neuromedin B receptor [17]. However, GRP stimula-
tion fails to activate MAPK in GRPR-deficient murine fibro-
blasts, indicating that GRP activates MAPK primarily through
GRPR, not NMBR (data not shown). In another report, GRPR
and NMBR have been demonstrated to have distinct func-
tions with only a partial overlap [18]. We have previously
demonstrated that in EGFR-deficient cells, GRP fails to
activate MAPK [9]. Our results indicate that through GRPR,
GRP activates MAPK primarily through EGFR in NSCLC
cells because EGFR abrogation reduces GRP-mediated
MAPK activation to baseline levels.
GRP could activate EGFR either through an extracel-
lular or an intracellular mechanism. We and others have
previously demonstrated that EGFR activation by GPCRs in-
volves extracellular ligand binding to EGFR in HNSCC [9,19]
and colon carcinoma cells [20]. Interestingly, the specific
ligands released from the membrane surface on GPCR
activation vary among different cell types. We found that in
NSCLC cells, both TGF-a and HB-EGF are involved in GRP-
mediated EGFR activation; whereas in HNSCC cells, HB-
EGF is not implicated [9]. TGF-a is commonly reported to
be involved in EGFR activation on GPCR stimulation in dif-
ferent cell types, including colon cancer and HNSCC [20,19].
EGFR ligands exist on the membrane surface as inactive
proligands. These proligands are activated by proteolytic
cleavage from the membrane surface into active extracellu-
lar ligands that can bind to EGFR. MMPs have been previ-
ously implicated in EGFR proligand processing [21]. Blocking
MMP activity with broad-spectrum MMP inhibitors such as
Marimastat and GM6001 in NSCLC cells abrogated MAPK
activation by GRP, implying that MMPs play a role in EGFR
ligand release from the membrane surface. This finding in
NSCLC cells is similar to the reported mechanism of EGFR
activation by GRP in HNSCC cells [9].
Our data suggest that GRPR contributes to NSCLC cell
proliferation, most likely by triggering the release of EGFR
ligands from the cell surface. Targeting GRPR with the
GRPR antagonist, PD176252, was cytotoxic to NSCLC cells
and corroborates previously reported effects in lung cancer
cells with a comparable IC50 dose [11]. Inhibition of GRPR
may severely limit the autocrine release of EGFR ligands in
both NSCLC and HNSCC, acting as a brake on EGFR sig-
naling. In addition, we demonstrated that 201T NSCLC cells
are susceptible to EGFR blockade using ZD1839 (gefitinib),
with an IC50 of 18 mM, near the reported IC50 for other
gefitinib-resistant NSCLC cells that lack EGFR mutations
[5,6]. Gefitinib combined with a GRPR antagonist showed
additive cytotoxic effects against NSCLC. Combination of the
GRPR antagonist with gefitinib at 1 to 2 mM (concentrations
that are similar to those currently achievable in serum with
daily gefitinib dosing in patients) resulted in up to 40% cell kill,
compared to 10% to 20% with gefitinib alone, whereas over
90% cell kill was achieved with high-concentration gefitinib
Figure 6. Targeting EGFR and GRPR has antitumor efficacy against NSCLC
in vitro. (A) NSCLC cells 201T were treated with increasing concentrations of
either EGFR inhibitor, ZD1839 (0–50 M), or GRPR antagonist, PD176252
(0–50 M), for 72 h followed by the MTT assay. The IC50 for ZD1839 (18 M)
and PD 176252 (8 M) was calculated using nonlinear regression analysis.
(B) NSCLC cells were treated with ZD1839 (15 M), PD176252 (5 M), or a
combination of both inhibitors for 72 hours prior to MTT assay. (C) NSCLC
cells were treated with ZD1839 (1 or 2 M), PD176252 (5 M), or a com-
bination of both inhibitors for 72 hours prior to MTT assay.
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(18 mM). Cytotoxicity in NSCLC with ZD1839/gefitinib at high
concentrations may be the result of achieving the ID50 for
gefitinib-resistant cells that lack EGFR mutation and may
also result in inhibition of other tyrosine kinases such as
erbB2 and PDGFR, increasing nonspecific killing. However,
using the current daily oral dose of gefitinib of 250 to 500 mg,
such high levels of drug cannot be achieved in patients [5].
There are new clinical trials in progress that will test inter-
mittent high-dose gefitinib, however, in an attempt to produce
transient serum levels high enough to inhibit the EGFR of
gefitinib-resistant cells. Agents such as GRPR antagonists
that could produce additive effects with EGFR inhibitors
could be useful in reducing the serum level of gefitinib
required for activity, or in prolonging or enhancing responses
to gefitinib in both sensitive and resistant cells.
Our results demonstrate that in NSCLC cells, GRPR
stimulation results in EGFR activation, triggering signal
transduction through the MAPK pathway. GRPR stimulation
also triggers cell proliferation, and combined targeting of
EGFR and GRPR may have additive antitumor effects in
NSCLC cells. Combined targeting may result in total EGFR
pathway blockade by inhibiting both the release of ligand and
the receptor tyrosine kinase. This might improve the efficacy
of EFGR tyrosine kinase inhibitors, especially in tumors that
lack activating EGFR mutations. This is the first report in
NSCLC cells demonstrating that GRPR can trigger signal
transduction pathways through EGFR, identifying targets for
combined antitumor therapy in NSCLC cells [22].
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